|
TME Pharma's Ordinary Shares • Date of the IPO: September 28, 2016 *Taking into account the shares issuance following the exercise of Warrants Z as published on March 28, 2025.
TME Pharma's Warrants Z • ISIN NL0015001SR3
Rapid access to French brokers
|
Aram Mangasarian, CEO: "We have received and taken note of a letter from a group of TME shareholders referred to in an article published on Dec 5th, 2024 on Boursorama.com (link). We thank the investors for their constructive engagement and support of TME’s strategic update and financing plans published on Dec 4th, 2024 (link)." « Nous avons reçu et pris note d'une lettre d'un groupe d'actionnaires de TME mentionnée dans un article publié le 5 décembre 2024 sur Boursorama.com (lien). Nous remercions les investisseurs pour leur engagement constructif et leur soutien à la mise à jour stratégique et aux plans de financement de TME publiés le 4 décembre 2024 (lien). » Analyst Coverage
TME Pharma N.V. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding TME Pharma’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of TME Pharma or its management. TME Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
|
 |
|||||||||
|
|
|||||||||||
